Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580

Article  PubMed  CAS  Google Scholar 

Farina A, Birzu C, Elsensohn MH et al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5(3):fcad169

Article  PubMed  PubMed Central  Google Scholar 

Farooq MZ, Aqeel SB, Lingamaneni P, Pichardo RC, Jawed A, Khalid S, Banskota SU, Fu P, Mangla A (2022) Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open 5(4):e227722

Article  PubMed  PubMed Central  Google Scholar 

Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R (2021) Immune checkpoint inhibitor–induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26(12):1052–1061

Article  PubMed  PubMed Central  Google Scholar 

Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976–986

Article  PubMed  CAS  Google Scholar 

Muppidi S, Wolfe GI, Conaway MR et al (2011) MG-ADL: still a relevant outcome measure. Muscle Nerve 44(5):727–731

Article  PubMed  Google Scholar 

Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70:327–334

Article  PubMed  Google Scholar 

Burns TM, Conaway MR, Sanders DB et al (2010) The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74:1434–1440

Article  PubMed  PubMed Central  Google Scholar 

Burns TM, Conaway MR, Cutter GR et al (2008) Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957-963

Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18(10):63

Article  PubMed  Google Scholar 

Marco C, Simo M, Alemany M et al (2022) Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series. J Clin Med 12(1):130

Article  PubMed  PubMed Central  Google Scholar 

Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127–1134

Article  PubMed  CAS  Google Scholar 

Huang YT, Chen YP, Lin WC, Su WC, Sun YT (2020) Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11:634

Article  PubMed  PubMed Central  Google Scholar 

Zadeh S, Price H, Drews R, Bouffard MA, Young LH, Narayanawami P (2024) Novel uses of complement inhibitors in myasthenia gravis-two case reports. Muscle Nerve 69(3):368–372

Article  PubMed  Google Scholar 

Nelke C, Pawlitzki M, Kerkhoff R et al (2023) Immune checkpoint inhibition-related myasthenia-myositis-myocarditis responsive to complement blockade. Neurol Neuroimmunol Neuroinflamm 11(1):e200177

Article  PubMed  PubMed Central  Google Scholar 

Fionda L, Rossini E, Lauletta A et al (2024) Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors. Neurol Sci 45(3):1243–1247

Article  PubMed  Google Scholar 

Masi G, Pham MC, Karatz T et al (2023) Clinicoserological insights into patients with immunecheckpoint inhibitor-induced myasthenia gravis. Ann Clin Transl Neurol 10(5):825–831

Article  PubMed  PubMed Central  CAS  Google Scholar